What's Happening?
Oslo-based Circio, a company specializing in circular RNA expression technology for gene and cell therapy, has entered into a collaboration with the Universidad de Santiago de Compostela (USC) in Spain.
This partnership, through USC's TraffikGene project, aims to explore the non-viral delivery of circVec circular RNA expression vectors. The collaboration combines Circio's circVec platform with TraffikGene's peptide amphiphile carrier system to enable high-throughput screening of circVec delivery with improved tissue targeting. The goal is to develop optimized formulations for prolonged, efficient, and targeted delivery of non-viral circVec vectors into specific cell and tissue types. The project will proceed in three stages: initial in vitro screening of peptide carriers with non-viral circVec vectors, physicochemical optimization of lead formulations, and in vivo evaluation in mouse models to assess expression kinetics, biodistribution, and delivery efficacy.
Why It's Important?
This collaboration is significant as it represents a potential breakthrough in the field of gene and cell therapy. By enhancing the delivery mechanisms of circular RNA vectors, the partnership could lead to more effective and safer gene therapies. The ability to target specific tissues with precision could revolutionize treatments for various genetic disorders and diseases, potentially reducing side effects and increasing therapeutic efficacy. The collaboration also highlights the growing importance of non-viral delivery systems, which are considered safer and less immunogenic compared to viral vectors. This development could have a substantial impact on the biotechnology industry, paving the way for new therapeutic applications and advancing the field of nucleic acid medicines.
What's Next?
The collaboration will move forward with the planned stages of research, starting with in vitro screenings and progressing to in vivo evaluations. The outcomes of these studies will determine the next steps in the development of the circVec platform. If successful, the research could lead to clinical trials and eventually the commercialization of new gene therapies. Stakeholders in the biotechnology and pharmaceutical industries will likely monitor the progress closely, as the results could influence future research directions and investment decisions in gene therapy technologies.
